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mcleasby@rvc.ac.ukAbstractInsulin resistance (IR) in skeletal muscle is an important component of both type 2 diabetes
and the syndrome of sarcopaenic obesity, for which there are no effective therapies.
Urocortins (UCNs) are not only well established as neuropeptides but also have their roles in
metabolism in peripheral tissues. We have shown recently that global overexpression of
UCN3 resulted in muscular hypertrophy and resistance to the adverse metabolic effects of a
high-fat diet. Herein, we aimed to establish whether short-term local UCN3 expression could
enhance glucose disposal and insulin signalling in skeletal muscle. UCN3 was found to be
expressed in right tibialis cranialis and extensor digitorum longus muscles of rats by in vivo
electrotransfer and the effects studied vs the contralateral muscles after 1 week. No increase
in muscle mass was detected, but test muscles showed 19% larger muscle fibre diameter
(PZ0.030), associated with increased IGF1 and IGF1 receptor mRNA and increased SER256
phosphorylation of forkhead transcription factor. Glucose clearance into the test muscles
after an intraperitoneal glucose load was increased by 23% (PZ0.018) per unit mass,
associated with increased GLUT1 (34% increase; PZ0.026) and GLUT4 (48% increase;
PZ0.0009) proteins, and significantly increased phosphorylation of insulin receptor
substrate-1, AKT, AKT substrate of 160 kDa, glycogen synthase kinase-3b, AMP-activated
protein kinase and its substrate acetyl coA carboxylase. Thus, UCN3 expression enhances
glucose disposal and signalling in muscle by an autocrine/paracrine mechanism that is
separate from its pro-hypertrophic effects, implying that such a manipulation may have
promised for the treatment of IR syndromes including sarcopaenic obesity.Key Words
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" urocortin 3
" glucose disposal
" GLUT4
" AMPK
" PI3K signallingicen
.0 UJournal of Endocrinology
(2014) 223, 143–154IntroductionImpaired insulin-stimulated glucose disposal into skeletal
muscle is a major component of the insulin resistance
(IR) that develops in advance of type 2 diabetes (T2D)
(DeFronzo & Tripathy 2009). In addition, obesity and IR
commonly also co-exist with muscular atrophy in theelderly in the syndrome of sarcopaenic obesity (Stenholm
et al. 2008, Narici & Maffulli 2010, Bassil & Gougeon
2013). Despite this affecting between 4 and 12% of the
elderly population (Stenholm et al. 2008) and there being
several identified common pathways involved in thesed under a Creative Commons
nported License.
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223 :2 144regulation of muscle size and insulin action (Rommel et al.
2001, Sandri et al. 2006, Cleasby et al. 2007, 2014, Lantier
et al. 2010), there are no effective treatments available.
However, recent work has demonstrated that generalised
overexpression of urocortin 3 (UCN3) in mice results in
both hypertrophy and increased glucose disposal into
muscle (Jamieson et al. 2011), making this an interesting
candidate for further study.
The UCNs comprise three neuropeptides (UCN1,
UCN2 and UCN3) with homology to corticotropin-
releasing factor (CRF) that are ligands for CRF receptors
(CRFR1 and R2) (Vaughan et al. 1995, Hsu & Hsueh 2001,
Lewis et al. 2001, Reyes et al. 2001). CRFR1 is well
established as the stress-coping receptor in brain regions,
modifying both physiological and behavioural functions.
However, CRFR2 and its specific ligands UCN2 and UCN3,
in addition to expression in specific brain regions, are also
expressed in discrete non-neural tissues in which direct
metabolic effects might be expected (Hsu & Hsueh 2001,
Lewis et al. 2001, Reyes et al. 2001).
CRFR2-knockout mice are resistant to high-fat diet
(HFD)-induced fat accretion and IR, despite unaltered
body weight and increased appetite (Bale et al. 2003),
apparently due to increased brown fat thermogenesis
(Carlin et al. 2006). Some of these effects are certainly
centrally mediated, as CRFR2 knockdown in the ventro-
medial hypothalamus (VMH) reduced adipose tissue
lipolysis and lipid oxidation (Chao et al. 2012). However,
UCN2 is expressed in brown adipose tissue and heart of
mice and demonstrates autocrine/paracrine cardioprotec-
tive effects mediated via ERK1/2, AKT and PKC3 activation
(Brar et al. 2002, 2004, Lawrence et al. 2005). UCN2 and
CRFR2 are both expressed in mouse skeletal muscle (Chen
et al. 2004, Keipert et al. 2013), where they inhibit atrophy
and promote hypertrophy (Hinkle et al. 2003, Chanalaris
et al. 2005, Reutenauer-Patte et al. 2012). UCN2-knockout
mice show increased whole-body insulin sensitivity and
resist the effects of an HFD, due to CRFR2-mediated
activation of AKT and ERK1/2 signalling in skeletal muscle
(Chen et al. 2006). Furthermore, CRF stimulates muscle
substrate oxidation through the activation of both
phosphoinositol 3-kinase (PI3K) and AMP-activated pro-
tein kinase (AMPK) pathways (Solinas et al. 2006).
Investigations into the role of UCN3 in metabolism
are less advanced. Injection of UCN3 into the VMH
elevated blood glucose and insulin levels and reduced
food intake (Chen et al. 2010), while overexpression of
UCN3 in the rostral perifornical area of the brain caused
increased energy expenditure but a reduction in insulin
sensitivity (Kuperman et al. 2010). The peripheral effectshttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great Britainof UCN3 are clearly significant, however, as global UCN3
knockout increased food intake and reduced insulin
sensitivity, while not affecting energy expenditure (Chao
et al. 2012). Importantly, UCN3 and CRFRs are expressed
in pancreatic b cells, where they facilitate insulin secretion
in response to high-glucose concentrations (Li et al. 2003,
2007). However, although UCN3 is not normally
expressed in skeletal muscle, transgenic global UCN3-
overexpressing mice showed high levels of UCN3
expression in skeletal muscle, associated with muscle
hypertrophy, elevated muscle insulin-like growth factor
1 (IGF1), reduced plasma glucose, improved glucose
tolerance and increased glucose disposal into muscle
(Jamieson et al. 2011). This occurred in the absence of
any effect on whole-body insulin sensitivity, although
plasma insulin levels and phosphorylation of insulin
signalling intermediates in muscle were reduced.
Thus it is likely that CRFR2-mediated effects of UCN3
on metabolism are exerted through distinct central and
peripheral actions. Given the positiveeffects ofUCN2 action
in skeletal muscle on glucose homeostasis and atrophy
resistance and the analogous results generated by whole-
body UCN3 overexpression, we aimed to establish whether
there might be a paracrine role for UCN3 to improve glucose
disposal in skeletal muscle in vivo after forced expression. To
this end, local overexpression of UCN3 was carried out in a
single muscle group and the effects compared with the
contralateral control muscles after just 1 week, to enable
assessment of the acute tissue-specific effects.Materials and methods
Materials
Molecular reagents were supplied by Promega Corp. and
general reagents by Sigma–Aldrich. Antibodies targeting
pY608-IRS1, total IRS1, AS160, GLUT1 and total glycogen
synthase kinase (GSK) 3a/b were purchased from Millipore
(Billerica, MA, USA), b-actin antibody from Sigma and all
others from Cell Signaling Technology (Danvers, MA, USA).Construction of UCN3 expression vector
pCR–TOPOII containing the full-length mouse UCN3
cDNA (Lewis et al. 2001) was consecutively digested with
EcoRI, the cDNA insert agarose gel-separated, extracted
using a QIAquick gel extraction kit (Qiagen) and
phosphorylated using polynucleotide kinase. The mUcn3
cDNA was then ligated into the dephosphorylated EcoRI-
linearised pCAGGS expression vector (Patel et al. 2012).Published by Bioscientifica Ltd
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Escherichia coli, and correct insertion of cDNA into clones
was verified by HindIII digestion and sequencing
of minipreps derived from colonies.Animals and in vivo electrotransfer
All experimental procedures were approved by the Royal
Veterinary College’s Ethics and Welfare committee and
were carried out under UK Home Office licence to comply
with the Animals (Scientific Procedures) Act 1986. Male
Wistar rats were obtained from Charles River (Margate,
UK) at 150–175 g and maintained at 22G0.5 8C under
a 12 h light:12 h darkness cycle on a standard chow diet
and acclimatised to their new surroundings for 1 week.
Preparation and injection of DNA, i.m. injection of
hyaluronidase and in vivo electrotransfer (IVE) of tibialis
cranialis (TC) and extensor digitorum longus (EDL)
muscles were carried out under isofluorane anaesthesia
as described previously (Cleasby et al. 2005, Patel et al.
2012). Right TCMs were injected with pCAGGS–mUCN3
and left TCMs with empty pCAGGS vector as within-
animal control. The rats were killed by pentobarbitone
injection for 1 week later and their muscles rapidly
dissected and weighed. The portions of each muscle were
fixed in 10% buffered formalin for 48 h and stored in 70%
ethanol, snap-frozen in liquid nitrogen-cooled isopentane
surrounded in OCT compound (Sakura Finetech, Alphen
aan den Rijn, The Netherlands) or freeze-clamped and
stored at K80 8C. A total of 26 rats were used.Glucose uptake into muscle
Half of the rats were starved overnight, and glucose uptake
into paired TC muscles was measured using an intra-
peritoneal glucose tolerance test (IPGTT), combined with
administration of 2-[1,2-3H(N)]-deoxy-D-glucose (3H-2DG;
Perkin-Elmer, Seer Green, Bucks, UK) tracer (Crosson et al.
2003, Cleasby et al. 2007, 2014). Briefly, w5 MBq 3H-2DG
in 2 mg/kg glucose was administered i.p. and blood samples
were collected for the measurement of glucose concen-
tration (Accu-chek Aviva glucometer, Roche Diagnostics)
and radioactivity immediately beforehand and 15, 30, 60
and 90 min afterwards. Plasma was separated, deprotei-
nised and counted in Ultima Gold scintillation fluid
(Perkin-Elmer) on a beta counter (LS6500, Beckman
Coulter, High Wycombe, UK). The powdered muscle was
homogenised in dH2O,
3H-2DG-6-phosphate separated
by passage through columns containing AG 1-X8 resin
(Bio-Rad) and similarly counted. Tissue glucose uptake washttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great Britainestimated by dividing the 3H-2DG-6-phosphate counts by
the plasma glucose-specific activity over 90 min and was
stated per unit muscle mass.Muscle glycogen content
Glycogen was extracted from muscles and quantified as
described previously (Chan & Exton 1976). Briefly, TC
muscle tissue was digested in 1 M KOH and glycogen
precipitated using Na2SO4 and ethanol. The glycogen
pellet was digested overnight at 37 8C using 0.3 mg/ml
amyloglucosidase in 0.25 M acetate buffer of pH 4.75.
Glycogen content was estimated as the quantity of glucose
detected at 490 nm in samples incubated in 0.12 M
phosphate buffer of pH 7.0 containing 0.5 mg/ml
4-aminoantipyrine, 1.6 U/ml peroxidase and 10 U/ml
glucose oxidase for 25 min at 37 8C, vs a standard curve.Determination of muscle fibre size and type distribution
The muscle fibre size was estimated in a blinded fashion
in transverse test and control muscle sections of TC
mid-belly that were immunostained for laminin using a
method adapted from that described previously (Cleasby
et al. 2007). Fixed tissue was paraffin wax-embedded and
10 mm sections were cut, dewaxed, rehydrated and then
antigen retrievalwascarried outusing10!Tris–EDTA buffer
(pH: 9.0) at 95 8C for 10 min. The sections were blocked for
30 min in blocking buffer (1! PBS, 0.5% Tween 20, 10%
goat serum) and incubated overnight with 1:200 rabbit
anti-laminin antibody (Sigma), followed by washing 3!
10 min in 1! PBS/ 0.5% Tween-20, incubation for 1 h with
1:1000 Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen)
secondary antibody and a further 3!10 min washes. The
sections were hydro-mounted and images captured using a
DM4000B upright microscope and Application Suite soft-
ware (Leica, Wetzler, Germany). Minimum Feret diameter
was measured usingLeica QWinsoftware forw600 fibres per
section and a mean value calculated for each muscle.
Fibre type distribution was determined by simul-
taneous immunostaining of myosin heavy-chain isoforms
(MHC) type I, IIa and IIb of 10 mm TC mid-muscle belly
cryosections as described previously (Cleasby et al. 2014)
using primary antibodies that were a kind gift from
Dr Keith Foster, University of Reading, UK. The primary
antibodies were visualised using 1:200 dilutions of Alexa
Fluor 488, 568 and 633 (Invitrogen) secondary antibodies
and the above microscope. The percentage of each fibre
type per section was calculated from counts of total
numbers of fibres (mean w1200 per muscle) and countsPublished by Bioscientifica Ltd
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223 :2 146of those immunoreactive for MHC I, IIa and IIb, with the
percentage of IIx fibres obtained by difference.Real-time PCR analysis
Extraction of RNA, preparation of cDNA and relative
quantitation of mRNA transcript levels corresponding to
most genes of interest was carried out by real-time PCR
assay using SYBR Green chemistry (Patel et al. 2012) and
primers and conditions described previously (Cleasby
et al. 2014). RNA concentration and quality were assessed
using a Nanodrop 1000 (Wilmington, DE, USA) and by
visualisation of ribosomal bands after agarose gel electro-
phoresis. As no SYBR assay could be successfully developed
to quantify total mouse and rat UCN3 expression, a mouse
UCN3 Taqman assay (Applied Biosystems Mm00453206-s1)
was performed to demonstrate relative expression of
mUCN3 in muscles vs a dilution series of pCR–TOPOII–
UCN3 plasmid. The results are quoted after normalisation
to the geometric mean of the mRNA levels of cyclophilin,
36B4 and 18S, expression of which were unchanged by
the treatments (data not shown).UCN3 RIA
EDL muscles were acid-extracted and partially purified
using octadecyl silica cartridges as described previously
(Li et al. 2003). The purified samples were lyophilised,
resuspended in RIA buffer and assayed at several concen-
trations. The production of antiserum, iodination and
purification of synthetic rat/mouse UCN3 (r/mUcn3)
analogue for use as tracer, and r/mUCN3 RIA buffers and
procedures were similar to those described in detail for
inhibin subunits (Vaughan et al. 1989). Briefly, the
analogue [Tyr0Nle12] r/mUCN3 was radiolabelled with
125I and purified by HPLC using a 0.1% trifluoroacetic
acid-acetonitrile solvent system and a diphenyl column.
R/m UCN3 antiserum was raised in rabbit using r/mUCN3
coupled to keyhole limpet haemocyanin via carbodiimide.
Rabbit 7255 anti-r/mUCN3 was used at a 1:300 000 final
dilution and synthetic r/mUCN3 was used as a standard.
The EC50 and minimal detectable dose for r/mUCN3
were 20 and 1 pg/tube respectively. Closely related CRF
family peptides displayed the following crossreactivities:
rUCN 1 and rCRF being !0.01%; mUCN 2, 0.5%. This
r/mUCN3 RIA employing rabbit 7255 antiserum showed
improved sensitivity over the RIA previously published
(Li et al. 2003); both assays detect UCN3 peptide in murine
brain and pancreas, the highest endogenously expressing
tissues, in similar quantities.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great BritainSDS–PAGE and immunoblotting
The muscle tissue was homogenised in RIPA buffer using
the Ultra-Turrax, followed by rotation for 90 min at 4 8C
and centrifugation for 10 min at 16 000 g, and the protein
content of the supernatants was quantified using the
bicinchoninic acid method (Pierce Biotechnology, Inc.,
Rockford, IL, USA) using a BSA standard, normalised to the
lowest concentration and denatured in Laemmli buffer for
10 min at 65 8C. The aliquots containing 40–80 mg protein
were resolved by SDS–PAGE, electro-transferred and
immunoblotted as described previously (Cleasby et al.
2007, Patel et al. 2012). Specific bands were detected
by chemiluminescence (Western Lightning Plus, Perkin-
Elmer, Waltham, MA, USA) on Fuji Super RX film
(Bedford, UK), scanned and quantified using Image
J software (NIH, Bethesda, MD, USA). Equal loading was
confirmed by blotting for GAPDH protein.Statistical analyses
The data are quoted as meanGS.E.M. Comparisons between
treated and control muscles were made using paired
Student’s t-tests, after confirming normality of data sets
using the Shapiro–Wilk test. The analyses were conducted
using Sigma Plot v11.2.0.5 (Systat Software, Inc., Chicago,
IL, USA), with P!0.05 regarded as significant.Results
Expression of mUCN3 in rat muscle increases fibre size
but does not affect total muscle mass or fibre type
distribution after 1 week
One week after IVE, expression of mUCN3 was substan-
tially increased at both the RNA (Fig. 1A) and protein
(Fig. 1B) levels in test muscles.mUcn3RNA was measured in
paired TC muscles and was below the limit of detection in
left muscles using this assay, consistent with reports that
UCN3 is not normally expressed in muscle (Jamieson et al.
2011). By way of comparison, test muscle mUcn3 mRNA
expression was several-fold higher than in a positive
control sample of mouse whole brain. mUCN3 immuno-
reactivity was measured in the extracts prepared from
whole EDLs and was increased by 4.2-fold in test vs control
muscles. Of note, we detected UCN3 peptide in mouse
skeletal muscle (Vaughan JM, unpublished observation) in
a different highly specific RIA previously described (Li et al.
2003) that displays minimal cross-reactivity with UCN2
(!0.01%). Because Ucn3 mRNA is not normally expressedPublished by Bioscientifica Ltd
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Figure 1
Expression of mUCN3 in rat skeletal muscle. Levels of (A) mouseUcn3mRNA
expression in test and paired control tibialis cranialis muscles compared
with a whole brain sample, measured using real-time PCR and (B) UCN3
peptide in test and control extensor digitorum longus muscles, measured
by RIA, 1 week after IVE. Data are meanGS.E.M. (nZ8). ***P!0.001 vs
paired control.
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derived from circulating sources. Nevertheless, it is clear
that there is substantially more UCN peptide in the
pCAGGS–UCN3 electroporated muscles. Unfortunately,
the available antibodies proved unsuitable for immuno-
fluorescence in muscle tissue, and therefore we could not
assess the transfection efficiency of UCN3 by this method.
However, the RIA data combined with the set of consistent
metabolic, gene expression and signalling data presented
below are suggestive that physiologically relevant concen-
trations of UCN3 were achieved.
There was a mean 19% increase in TC fibre diameter
over this period in mUCN3-expressing muscles (PZ0.030;
Fig. 2A, B and C), which was not accompanied by a change
in the coefficient of variation between test and control
muscles (data not shown). However, this short duration of
expression was not sufficient to affect the mass of whole
TC or EDL muscles (TC: test 0.378G0.018 g, control
0.379G0.014 g; EDL: test 0.133G0.0053 g, control
0.135G0.0045 g; nZ10). In addition, the percentage of
type I, IIa, IIb and IIx fibres comprising each TC muscle
was not altered at this time point (Fig. 2D, E, F, G and H;
nZ6–8), although it seemed that there was a tendency for
there to be fewer IIx (PZ0.07) and more IIb (PZ0.08) fibres
in mUCN3-expressing muscles.mUCN3 expression is associated with increases in the
expression of IGF and its receptor, but also of selected
pro-atrophic genes
In order to establish whether particular pro-hypertrophic
or pro-atrophic pathways were activated at this early timehttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great Britainpoint of local UCN3 expression in TC muscle, potentially
explaining the modest increase in muscle fibre size
observed, expression and activation of key mediators in
these pathways were assessed using real-time PCR and
immunoblotting. Firstly, consistent with the effects of
transgenic overexpression (Jamieson et al. 2011), mRNA
expression of both IGF1 and IGF1R were upregulated in
UCN3 OE muscles (by 87 and 1067%, PZ0.049 and
PZ0.014 respectively; Fig. 3A). Secondly, pS256–FOXO1
was increased by the manipulation (by 22%, PZ0.032;
Fig. 3C/E), implying the inhibition of its transcriptional
activity. However, although increased FOXO1 activity
would be expected to suppress the expression of
pro-atrophic E3 ubiquitin ligases (Stitt et al. 2004), in fact
mRNA levels of both MURF1 and Atrogin1 were slightly
increased in these muscles (by 17 and 15%, PZ0.049 and
P!0.001 respectively; Fig. 3B).
mRNA expression of the pro-atrophic transforming
growth factor-b family member myostatin was in fact
increased (by 45%, PZ0.030; Fig. 3B). However, this effect
would be unlikely to limit increases in muscle size, as
expression of its receptor, the activin 2B receptor, was
reduced by 60% (PZ0.042; Fig. 3B; Lee & McPherron 2001,
Cleasby et al. 2014). Furthermore, mRNA expression of
latent transforming growth factor b-binding protein-3
(LTBP3), which impairs myostatin signalling (Anderson
et al. 2008), was increased (by 233%, PZ0.010; Fig. 3A).
Finally, no change in mighty (akirin-1) expression, a
downstream target of myostatin in muscle (Marshall et al.
2008), was detected (Fig. 3A).
Although there was a small increase in total p70S6k
protein (by 15%, PZ0.011), no change in pT389–p70S6k
was shown (Fig. 3D/E), suggesting that this kinase was not
involved in the phenotype. In addition, mRNA expression
of the pro-atrophic NFkB–p65 subunit was also unaffected
by forced UCN3 expression (Fig. 3B).mUCN3 expression enhances glucose uptake into
muscle during an IPGTT and increases cellular glucose
transporter content
Glucose uptake into mUCN3 expressing and paired
control TC muscles were also assessed after 1 week. The
IPGTTs carried out in these rats resulted in typical plasma
glucose excursions (data not shown). Despite the lack of
effect on gross muscle mass, glucose uptake into test
muscles was enhanced (by 23%, PZ0.032; Fig. 4A) on a
per unit mass basis, implying that UCN3 mediates enhan-
ced muscle glucose disposal by a mechanism that is not
totally dependent on hypertrophy. The enhanced glucosePublished by Bioscientifica Ltd
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Figure 2
Expression of mUCN3 for 1 week resulted in increased muscle fibre size
in the absence of a change in muscle mass, and no change in fibre type
distribution. Muscle fibre diameter was measured in fixed transverse
sections of TC muscles immunostained for laminin. Representative sections
from (A) control and (B) mUCN3-expressing muscles are accompanied by (C)
summary data. The percentage of each fibre type present in TC muscles was
calculated after immunostaining of frozen transverse sections for type I, IIa
and IIb fibres, with type IIx fibres indicated by lack of immunostaining.
(D) Control and (E) mUCN3-expressing muscles immunostained for type I
myosin heavy chain (MHC; red) and laminin (green). (F) Control and (G)
mUCN3-expressing muscles immunstained for type IIa MHC (green) and
type IIb MHC (red). (H) Summary fibre type distribution. Scale bars: 100 mm,
nZ6–8. Data are meanGS.E.M. *P!0.05 vs paired control. Black bars,
control; white bars, UCN3 IVE muscle.
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223 :2 148disposal was associated with increases in total cell levels of
both the GLUT1 (by a mean 34%, PZ0.026; Fig. 4B/D) and
GLUT4 (by a mean 48%, PZ0.0009; Fig. 4C/D) glucose
transporter proteins. The associated increased capacity
for insulin-stimulated glucose uptake likely contributed to
the increased clearance observed and these data suggest
that basal glucose uptake may also be increased by muscle
UCN3 expression. However, glycogen storage by the
muscles at the 1 week time point was unaffected (data
not shown), suggesting that the additional glucose taken
up is being utilised rather than stored.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great BritainmUCN3 expression increases both phosphorylation and
total protein expression of PI3-kinase pathway signalling
intermediates
To assess whether muscle mUCN3 expression might also
impact glucose disposal through increased activation of
the PI3-kinase signalling pathway, protein expression
levels and phosphorylation of intermediates at regulatory
residues were assessed in lysates generated from paired
TC muscles removed from fed, otherwise untreated rats.
Interestingly, significant increases were detected in bothPublished by Bioscientifica Ltd
16A C D EB
1.8 1.4
1.2
1.0
0.8
0.6
0.4
0.2
0.0
1.4
pS256-FOXO1
FOXO1
pT389-p70S6k
p70S6k
GAPDH
C T C T
1.2
1.0
0.8
0.6
0.4
0.2
0.0
Control mUcn3 IVE Control
R
el
at
ive
 p
70
S6
k 
pr
ot
ei
n 
ex
pr
es
sio
n
R
el
at
ive
 p
S2
56
 F
OX
O
1 
ex
pr
es
sio
n
R
el
at
ive
 m
R
N
A 
ex
pr
es
sio
n
R
el
at
ive
 m
R
N
A 
ex
pr
es
sio
n
mUcn3 IVE
1.5
1.2
0.9
0.6
0.3
0.0
Co
ntr
ol
My
os
tat
in
Ac
tivi
n 2
BR
MU
RF
1
Atr
og
in1
NF
kB
 p6
5
14
12
4
2
0
Control IGF1
*
*
**
*
*
*
*
* ***
IGF1R LTBP3Mighty
Figure 3
Muscle UCN3 expression has contrasting effects on mediators of muscle
hypertrophy and atrophy. Effects of local muscle UCN3 expression on
relative mRNA and protein expression and phosphorylation of key
mediators in pathways regulating muscle mass. Expression data were
obtained by real-time PCR analysis of mRNA extracted from mUCN3-
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(A) mRNA levels of pro-hypertrophic genes: IGF1, IGF1 receptor (IGF1R),
mighty (akirin1) and latent transforming growth factor-b 3 (LTBP3).
(B) mRNA levels of pro-atrophic genes: myostatin, activin IIB receptor
(activin 2BR), muscle ring finger protein 1 (MURF1), atrogin1 and the p65
subunit of nuclear factor kB (NFkB–p65). (C) pS256–FOXO1 and (D) p70S6k
total protein levels and (E) sample immunoblots are shown. Total FOXO1
protein and pT389–p70S6k were not affected by forced UCN3 expression.
C, control; T, test. Data are meanGS.E.M.; nZ8; *P!0.05, **P!0.01,
***P!0.001 vs paired control.
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223 :2 149phosphorylation and total protein levels of all the
intermediates assessed in UCN3-electroporated muscles,
in the absence of any effect on either GAPDH or b-actin
levels. Specifically, pY612-IRS1 and total IRS1 were
increased by 38 and 15% respectively (PZ0.008 and
PZ0.024; Fig. 5A/B/I), pS473–AKT and total AKT were
increased by 72 and 30% (PZ0.005 and PZ0.0003;
Fig. 5C/D/I), pT642–AKT substrate of 160 kDa (AS160)
and total AS160 by 24 and 12% (PZ0.026 and PZ0.047;
Fig. 5E/F/I) and pS9–GSK3b and GSK3b both by 40%
(PZ0.0011 and PZ0.0002; Fig. 5G/H/I). Phosphorylation
and protein levels of GSK3a were unaltered (Fig. 5I). Thus
the UCN3-induced increase in glucose disposal may also
be contributed to by increased flux through the PI3-kinase
pathway from at least the level of IRS1, likely mediated
by the increased IGF1 binding to its receptor (Fig. 3A;
Rommel et al. 2001, Jamieson et al. 2011).
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Figure 4
mUCN3 expression enhances muscle glucose disposal and increases protein
levels of GLUT1 and GLUT4 glucose transporters. (A) Glucose uptake into
paired TC muscles, estimated using 2-[1,2-3H(N)]-deoxy-D-glucose tracer
during an intraperitoneal glucose tolerance test. Summary data for (B)
GLUT1 and (C) GLUT4 protein contents quantified by western immuno-
blotting of mUcn3 expressing and paired control muscle lysates, normalised
to control. (D) Sample immunoblots for GLUT1, GLUT4 and GAPDH, which
was unaltered by the manipulation. Data are meanGS.E.M., nZ8–9.
*P!0.05, ***P!0.001 vs paired control.mUCN3 expression also activates AMPK in muscle
As muscle glucose uptake is also mediated by activation of
AMPK, phosphorylation and protein expression of AMPK
and its substrate acetyl coA carboxylase (ACC) were
quantified by western blotting analysis. UCN3 expression
resulted in a 27% increase in pT172–AMPK (PZ0.024;
Fig. 6A/E), implying increased activation, accompanied by a
consistent 59% increase in pS79–ACC (PZ0.0001; Fig. 6B/E)
and also an increase in total ACC protein (by 36%, PZ0.023;
Fig. 6C/E). Total AMPK protein remained unchanged.
However, surprisingly, PGC1a levels were reduced (by 44%,
PZ0.0020; Fig. 6D/E) implying that the AMPK activation
would be unlikely to result in increased mitochondrialhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great Britainbiogenesis and oxidation (Wu et al. 1999, Mootha et al.
2003). Nevertheless, our findings imply that multiple
changes in signalling molecules that promote glucose uptake
arise as a result of UCN3 expression in TC muscle.Published by Bioscientifica Ltd
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Figure 5
Enhanced muscle glucose disposal is associated with increased phos-
phorylation and protein levels of phosphoinositol 3-kinase pathway
intermediates. Western immunoblotting for phosphorylation of regulatory
residues and total protein content of PI3-kinase pathway intermediates
was undertaken using mUCN3 expressing and paired control TC muscle
lysates. Summary data for (A) pY612-IRS1, (B) total IRS1, (C) pS473–AKT,
(D) total AKT, (E) pT642-AS160, (F) total AS160, (G) pS21–GSK3b and (H)
total GSK3b are shown. (I) Sample immunoblots for each protein target and
GAPDH, levels of which were unchanged by the manipulation, as were
pS21–GSK3a and total GSK3a. Data are meanGS.E.M., nZ8. *P!0.05,
**P!0.01, ***P!0.001 vs paired control.
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In this study, we aimed to establish the effects of a short
period of local overexpression of UCN3 on glucose
disposal by skeletal muscle to identify the potential
molecular mediators of any effect. This manipulation
resulted in a modest increase in myofibre diameter in the
electroporated muscle, but did not generate a detectable
difference in whole-muscle mass after only 1 week,
analogous to the dose-dependent effects of UCN2 peptide
administration to mice (Hinkle et al. 2003). However,
UCN3 expression enhanced glucose disposal in treated vs
paired control TC muscles on a per unit mass basis,
indicating that this effect of UCN3 expression is at least in
part exerted through an autocrine/paracrine mechanism
and also that it was not an indirect effect of increased
muscle mass. This positive effect on glucose disposal
occurred after administration of a glucose load and may
have been mediated by the activation of the insulin
signalling pathway, the concurrent AMPK activation
and/or the increased GLUT1/4 protein expression
observed.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great BritainThe 1 week time point was chosen to give the UCN3
construct time for expression and to minimise any
inflammation resulting from the IVE procedure (Cleasby
et al. 2005), while avoiding the longer term effects that
gross hypertrophy might have on glucose disposal and the
potential confounding effects of the whole-body germ-
line manipulation carried out previously (Jamieson et al.
2011). Nevertheless, increased muscle fibre diameter was
observed and this was associated with elevations in
both IGF1 and IGF1R expression, indicating that gross
hypertrophy consistent with our previously published
work (Jamieson et al. 2011), the effects of UCN2 (Hinkle
et al. 2003, Reutenauer-Patte et al. 2012) and the pro-
hypertrophic effects of all UCNs in cardiomyocytes
(Chanalaris et al. 2005), would likely develop after a
longer period of forced expression. It is known that IGF1 is
sufficient to cause activation of the PI3K–AKT pathway
and both increased muscle mass and glucose uptake (Di
Cola et al. 1997, Rommel et al. 2001, Palazzolo et al. 2009),
but the details of the signalling mechanisms whereby
elevated IGF1 might impact upon these parameters was
unclear in our previous work (Jamieson et al. 2011).Published by Bioscientifica Ltd
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Muscle mUCN3 expression increases activation of AMPK but decreases
PGC1a. Western immunoblotting for (A) pT172–AMPK, (B) pS79–ACC, (C)
total ACC and (D) total PGC1a protein was undertaken using mUCN3
expressing and paired control TC muscle lysates. Summary data and (E)
sample immunoblots for each protein target and the loading control
GAPDH are shown. Levels of total AMPK and GAPDH proteins were
unchanged by the manipulation. Data are meanGS.E.M., nZ8. *P!0.05,
***P!0.001 vs paired control.
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223 :2 151In addition to the observed inconsistency between
increased insulin sensitivity in CRFR2 and UCN2-knock-
out mice (Bale et al. 2003, Carlin et al. 2006, Chen et al.
2006) and increased glucose tolerance in the absence of
any effect on insulin sensitivity in UCN3-overexpressing
mice (Jamieson et al. 2011), localised UCN3 expression
in muscle resulted in an increase in glucose uptake
associated with changes in signalling consistent with
increased muscle insulin sensitivity after a glucose load.
These differences are probably related with the universal
changes in UCN3 or CRFR2 expression having disparate
influences on central and peripheral control mechanisms
or feedback effects of pronounced hypertrophy on AKT
and/or AMPK signalling. The study described here
compared the effects of acute local UCN3 expression in
muscle vs a within-animal control and therefore permits
a clearer insights into the direct autocrine/paracrine
effects of UCN3 in muscle.
The UCN3-mediated increase in glucose uptake was
associated with the phosphorylation of a number of
intermediates in both the PI3K–AKT–FOXO1 and AMPK
signalling pathways, indicating increased activity, both or
either of which could mediate this effect. In addition, total
protein levels of many of these molecules were also
increased, suggesting an effect of UCN3 expression at the
level of translation or above. Consistent with this, we
observed increased uncoupling protein and IGF1 mRNA in
UCN3 transgenic mice (Jamieson et al. 2011), while UCNs
have also been shown to activate transcription factors in
macrophages (Tsatsanis et al. 2006). These data contrast
with the reduced IRS1 and AKT phosphorylation observed
in the transgenic mice (Jamieson et al. 2011), which may
have been the result of the reduced circulating insulin
levels or a compensatory effect for the chronic global
overexpression. In support of a role for both the PI3K andhttp://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
 2014 The authors
Printed in Great BritainAMPK pathways in mediating the effects of short-term
mUCN3 expression in muscle, CRF was shown to cause
increased substrate oxidation in muscle that relied on
both AMPK and PI3K activation (Solinas et al. 2006). In
contrast, UCN2 increased glucose uptake in the heart
through a mechanism that required AMPK but not AKT
activation (Li et al. 2013), while the hypertrophic effects
required AKT (Chanalaris et al. 2005). However, in
addition, AMPK activation may have beneficial effects on
muscle mass through the inhibition of apoptosis and
promotion of normal autophagy (Luo et al. 2013). Thus,
additional research is still required to assess the import-
ance of each pathway in the phenotype of enhanced
glucose disposal and muscular hypertrophy and to
establish how they are being activated by UCN3.
Acute UCN3 expression did not alter glycogen storage
in the rat muscles, while the increased glucose uptake
in global UCN3-overexpressing mice was reflected in
increased glycogen storage (Jamieson et al. 2011), imply-
ing either that utilisation was also increased in the IVE test
muscles, or that this is a feature of longer term expression.
The observed reduction in PGC1a levels also suggests
that UCN3 does not have the mitochondrial preservation
effects recorded in cardiac muscle (Kuizon et al. 2009). This
effect does not seem to be the result of a UCN3-mediated
shift towards type II glycolytic fibres, as seen in the trans-
genic model, as type I fibre percentage was unchanged,
although this again may reflect the short timescale of the
study. In addition, as the majority of the data presented
have been obtained in the predominantly fast twitch TC
muscle, it may be that muscles with alternative fibre
compositions would demonstrate different results. In
addition, we observed increased expression of pro-
atrophic pathways in this model, which might seem
surprising at first glance, given that activation of AKTPublished by Bioscientifica Ltd
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2004, Latres et al. 2005). It may be that this reflects
counter-regulatory changes in the activity of an alterna-
tive transcription factor, for example FOXO3 (Zheng et al.
2010), or that our data corroborate the recently published
work that implies a requirement for atrogin as part of the
process of remodelling involved in muscular hypertrophy
(Baehr et al. 2014).
The effect of local UCN3 expression on muscle fibre
size and the further enhancement of glucose disposal
beyond the level that would be expected purely as a
result of the hypertrophy is very similar to the phenotype
we observed recently after adeno-associated virus-
mediated local inhibition of myostatin action in muscle
(Cleasby et al. 2014), despite the modest upregulation of
myostatin mRNA we observed here, which has also been
observed in another model of rat muscle hypertrophy
(Abo et al. 2012). The effects of myostatin inhibition
occurred despite a reduction in IGF1 expression and
reduced activating phosphorylation of AMPK and AKT,
but as here, increased levels of cellular GLUT1 and
GLUT4 proteins resulted, implying increased capacity for
both basal and insulin-stimulated glucose uptake. How-
ever, we have not as yet established a causal link between
these variables, while glucose clearance into muscle is
determined not only by the capacity for transporter-
mediated facilitated diffusion, but also by other physio-
logical variables, including capillary density, vascular
smooth muscle tone and hexokinase activity. Notably,
UCN3 has been shown to cause arterial vasodilatation
(Venkatasubramanian et al. 2013), thus a paracrine effect
of mUCN3 on muscle arterioles could also contribute to
the observed effect. Nevertheless, targeting of CRFR2 or
myostatin in muscle may therefore provide potential for
treatment of IR and atrophic syndromes to complement
nutrition and exercise-based interventions (Bassil &
Gougeon 2013). Although UCN3 is not normally
expressed in rodent muscle, it is expressed in human
muscle (Hsu & Hsueh 2001), suggesting that interven-
tions targeting this pathway may be of more physiologi-
cal relevance in this species.
Thus, we have shown that forced expression of UCN3
in skeletal muscle enhances local glucose uptake by
an autocrine/paracrine mechanism associated with acti-
vation of both PI3-kinase-Akt and AMPK pathways and
increased glucose transporter expression. This occurs in
addition to a hypertrophic effect, implying that local
CRFR2 agonism may be a useful therapeutic approach in
the treatment of IR syndromes including T2D and
sarcopaenic obesity.http://joe.endocrinology-journals.org
DOI: 10.1530/JOE-14-0181
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